Article
The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19
Rating:
0.0
Views:
104
Likes:
1
Library:
1
Nestlé surprised few this summer when they spent $2.6 billion to buyout Aimmune. The Swiss Butterfingers-and-health conglomerate had long shown more interest in them and Palforzia, their recently approved peanut allergy treatment, than any of the traditional Big Pharmas. When talks began, though, in the second quarter, Aimmune was only
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value